SUPPLEMENTAL TABLE S1: Efficacy outcomes by RECIST 1.1

Response	**No. of patients (%)**
Confirmed CR	0
Confirmed PR	4(20%)
ORR (confirmed CR + confirmed PR)	4(20%) (95% CI: 5.7-43.7%)
Stable disease	13(65%)
SD < 12 weeks	3(15%)
SD >= 12 weeks	10(50%)
SD >=24 weeks	6(30%)
CBR (CR+PR+SD >= 24 weeks)	10(50%) (95% CI: 27.2-72.8%)
Progressive disease	2(10%)
Not Evaluable	1(5%)
Median duration of response (mo., 95% CI)	10.07 (3.06 – NA)
Median time to response (mo., 95% CI)	NA (3.02 – NA)
Median PFS, months (95% CI)	9.59 (2.76 – 16.06)
Median OS, months (95% CI)	NR (11.24 – NR)

CBR, clinical benefit rate; CI, confidence interval; CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease.

SUPPLEMENTAL TABLE S6: Efficacy outcomes by RECIST 1.1, based on PD-L1 and TIL status

	PD-L1 (evaluable in N=14)				**TILs (evaluable in N=14)**	
	(CPS ≥ 1) N=8	**(CPS < 1) N=6**	**(CPS ≥ 10) N=2**	**(CPS < 10) N=12**	**≥10% N=7**	**< 10% N=7**
ORR	25% (3.2-65.1)	33% (9.7-70)	0% (0-84.2)	33.3% (9.9-65.1)	0 (0-41)	57.1% (18.4-90.1)
CBR	37.5% (8.5-75.5)	67% (30-90.3)	50% (1.3-98.7)	50% (21.1-78.9)	28.6% (3.7-70.9)	71.4%(29-96.3)
PFS, median	6.2 mo (1.0 – NR*)	6.1 mo (1.4 – NR)	9.6mo (NR-NR)	2.9mo (1.4-14.4)	9.6 mo (1.0- NR)	6.1 mo (1.4-14.4)
Duration of response, median	10.1 mos (8.4 – 11.7)	NA (3.1 – NR)	NA	10.1 mos (3.1 – NR)	NA	10.1 mos (3.1 – NR)

CPS, combined prognostic score; ORR, overall response rate; PFS, progression-free survival; TILs, tumor infiltrating lymphocytes.